On 12 August 2024, Sandoz formally announced the introduction of Jubbonti® and Wyost® in Canada via its Canadian website. We previously reported in July 2024 Sandoz’s (informal) announcement via Linkedin that the company had launched its denosumab biosimilar Wyost® in Canada.
Wyost® was the first denosumab biosimilar approved in Canada in March 2024 for all Xgeva® indications, including the prevention of bone fractures in bone metastatic cancers and treatment of bone giant cell tumours in adults. This followed the Canadian approval of Sandoz’s Jubbonti® in February 2024 for osteoporosis and increasing bone mass.
Sandoz has 7 biosimilars approved in Canada. Sandoz’s Wyost® and Jubbonti® were the first denosumab biosimilars approved in the US in March 2024. Following the April 2024 resolution of US BPCIA proceedings commenced by Amgen against Sandoz in May 2023, Jubbonti® and Wyost® are expected to launch in the US from 31 May 2025.